Status:
RECRUITING
Clinical Study on the Safety and Efficacy of B7H3 CAR T Cells in Patients With B7H3 Positive Solid Tumors
Lead Sponsor:
Guangzhou Bio-gene Technology Co., Ltd
Conditions:
Solid Tumors
Eligibility:
All Genders
1-75 years
Phase:
NA
Brief Summary
This single-arm, single-center investigator-initiated trial (IIT) evaluates the safety, efficacy, and pharmacodynamic (PD)/pharmacokinetic (PK) profiles of CAR-T cells in patients with advanced solid ...
Eligibility Criteria
Inclusion
- The patient fully understands the study procedures and voluntarily signs the informed consent form.
- Patients diagnosed with tumors that demonstrate positive B7H3 expression in tumor tissues as confirmed by immunohistochemistry (IHC).
- Presence of at least one extracranial lesion that is measurable according to the RECIST 1.1 criteria;
- Estimated survival duration of ≥12 weeks;
- Eastern Cooperative Oncology Group (ECOG) performance status score of ≤1 at baseline;
- Recovery from prior treatment-related toxicities to a level below Grade 2.
- Adequate hematopoietic and organ function without severe impairment;
- Availability of suitable venous access for leukapheresis, with no contraindications to the collection of white blood cells.
Exclusion
- Patients with a history of or currently diagnosed with other malignant tumors;
- Presence of brain metastases or clinically significant central nervous system (CNS) disorders;
- Prior treatment within 14 days or five half-lives (whichever is longer) before blood collection for CAR-T preparation that may interfere with lymphocyte expansion;
- HIV+，HBV，HCV，EBV，CMV.
- Positive T-cell interferon-gamma release assay or sputum smear for tuberculosis;
- Documented history or current evidence of pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiation pneumonitis, drug-induced pneumonitis, or significant pulmonary dysfunction;
- History of severe allergic reactions or known hypersensitivity to any component of the investigational drugs used in the study;
- Severe cardiovascular disease or uncontrolled refractory hypertension, unless deemed stable and non-interfering with the study by the investigator;
- Severe hepatic or renal dysfunction, or presence of altered mental status;
- Active autoimmune or inflammatory neurological disorders;
- Presence of uncontrolled infections requiring systemic antibiotic, antifungal, or antiviral therapy;
- Receipt of (attenuated) live vaccines within 4 weeks prior to screening;
- Individuals with a history of alcohol dependence or substance abuse;
- Pregnant or lactating women.
Key Trial Info
Start Date :
August 31 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 31 2028
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT07152236
Start Date
August 31 2025
End Date
August 31 2028
Last Update
September 3 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dongguan Taixin Hospital
Dongguan, Guangdong, China, 523125